2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-112692
    AT-121 2099681-31-7
    AT-121 is a bifunctional nociception and mu opioid receptor agonist, with Kis of 3.67 and 16.49 nM, respectively. AT-121 is a safe, non-addictive analgesic, and shows antinociceptive and antiallodynic effects.
    AT-121
  • HY-112828
    LEI105 1800327-36-9 98%
    LEI105 is a potent, highly selective and reversible dual diacylglycerol lipase (DAGL)-α/DAGL-β inhibitor. LEI105 reduces 2-arachidonoylglycerol levels in Neuro2A cells. LEI105 also reduces cannabinoid CB1-receptor-mediated short-term synaptic plasticity in a mouse hippocampal slice model. LEI105 is promising for research of diseases, such as obesity, related metabolic disorders and neuroinflammation.
    LEI105
  • HY-112840
    ST3932 1246018-21-2 98%
    ST3932 is a metabolite of ST1535, acts as an antagonist of adenosine A2A receptor, with Kis of 8 nM and 33 nM for A2A and A1 receptors, respectively.
    ST3932
  • HY-113037
    (E/Z)-Farnesyl pyrophosphate 13058-04-3 98%
    (E/Z)-Farnesyl pyrophosphate ((E/Z)-Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. (E/Z)-Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. (E/Z)-Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis.
    (E/Z)-Farnesyl pyrophosphate
  • HY-113038
    D-α-Hydroxyglutaric acid 13095-47-1 ≥98.0%
    D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a Ki of 10.87 mM. D-α-Hydroxyglutaric acid increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid binds and inhibits ATP synthase and inhibits mTOR signaling.
    D-α-Hydroxyglutaric acid
  • HY-113050
    2,3-Diphosphoglyceric acid 138-81-8 98%
    2,3-Diphosphoglyceric acid (2,3-DPG) is an intermediate of the glycolytic pathway. 2,3-Diphosphoglyceric acid stabilizes the deoxygenated form of hemoglobin by allosteric binding and facilitates oxygen release at tissue sites. 2, 3-diphosphoglyceric acid has antiparasitic activity. 2,3-Diphosphoglyceric acid can be used in the study of Alzheimer's disease (AD).
    2,3-Diphosphoglyceric acid
  • HY-113084
    L-Cysteine S-sulfate 1637-71-4 98%
    L-Cysteine S-sulfate is a potent N-methyl-d-aspartate (NMDA) glutamatergic receptor agonist. L-Cysteine S-sulfate is the substrate for cystine lyase, and can be used in mass spectrometry operations.
    L-Cysteine S-sulfate
  • HY-113231
    3-(3-Hydroxyphenyl)-3-hydroxypropanoic acid 3247-75-4 98%
    3-(3-Hydroxyphenyl)-3-hydroxypropanoic acid is an endogenous metabolite present in Urine that can be used for the research of Autism.
    3-(3-Hydroxyphenyl)-3-hydroxypropanoic acid
  • HY-113356
    m-Tyramine 588-05-6 98%
    m-Tyramine is an endogenous trace amine neuromodulator. m-Tyramine has effects on the adrenergic and dopaminergic receptor[1, 2].
    m-Tyramine
  • HY-113516
    20-HETE Ethanolamide 942069-11-6 98%
    20-HETE Ethanolamide is a metabolite of endocannabinoid Anandamide. 20-HETE Ethanolamide binds to the rat brain cannabinoid CB1 receptor with a Ki of 985 nM.
    20-HETE Ethanolamide
  • HY-113575
    Dehydroaripiprazole hydrochloride 1008531-60-9 98%
    Dehydroaripiprazole (OPC-14857) hydrochloride is an active metabolite of Aripiprazole. Aripiprazole is an antipsychotic agent and is metabolized by CYP3A4 and CYP2D6 forming mainly Dehydroaripiprazole hydrochloride. Dehydroaripiprazole hydrochloride has with antipsychotic activity equivalent to Aripiprazole.
    Dehydroaripiprazole hydrochloride
  • HY-113608
    VCP171 1018830-99-3 98%
    VCP171 is a potent adenosine A1 receptor (A1R) positive allosteric modulator (PAM). VCP171 is effective at decreasing excitatory synaptic currents in Lamina II of neuropathic pain model. VCP171 can be used for researching neuropathic pain.
    VCP171
  • HY-113616
    VU0364572 1240514-87-7 98%
    VU0364572 is a selective allosteric agonist of the M1 muscarinic receptor with an EC50 of 0.11 μM. VU0364572 has neuroprotective potential for preventing memory impairments and reducing neuropathology in Alzheimer’s Disease. VU0364572 is orally active and is CNS penetrant.
    VU0364572
  • HY-113631
    Amorfrutin B 78916-42-4 98%
    Amorfrutin B is a highly potent natural peroxisome proliferation-activated receptor γ (PPARγ) agonist with oral activity with Ki values of 19 nM and EC50 values of 73 nM, respectively. Amorfrutin B has hypoglycemic and neuroprotective activities.
    Amorfrutin B
  • HY-113639
    A-933548 1037826-43-9 98%
    A-933548 is a potent and selective inhibitor of calpain, with a Ki of 18 nM. A-933548 can be used for the research of Alzheimer's disease.
    A-933548
  • HY-113643
    Levemopamil hydrochloride 101238-54-4 98%
    Levemopamil hydrochloride is a blood-brain barrier penetrable calcium channel blocker and a 5-HT2 antagonist. Levemopamil hydrochloride can be used for temporary occlusion and neurological disease research.
    Levemopamil hydrochloride
  • HY-113726
    Nerisopam 102771-12-0 98%
    Nerisopam is an orally active gamma-aminobutyric acid (GABA) receptor agonist. Nerisopam is an anxiolytic and antipsychotic homophthalazine. Nerisopam induces rapid, intense expression of Fos-like immunoreactivity in the rostral, dorsomedial and lateral parts of the striatum in the rat.
    Nerisopam
  • HY-113739
    Desmethylcitalopram hydrochloride 97743-99-2 98%
    Desmethylcitalopram (DCIT) hydrochloride is the active metabolite of Citalopram (HY-121203). Desmethylcitalopram has antidepressant effects. Desmethylcitalopram also inhibits cytochrome P450-2D6, -2C19 with IC50s of 39.5 and 53.5 μM.
    Desmethylcitalopram hydrochloride
  • HY-113745
    LX-6171 914808-66-5 98%
    LX-6171 is an orally active SLC6A7 inhibitor. LX-6171 can be used to study diseases characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia.
    LX-6171
  • HY-113802
    VUF 8328 102203-17-8 98%
    VUF 8328 is a potent histamine H(3) receptor agonist. VUF 8328 inhibits the electrically-evoked [3H]-no-radrenaline release from rat cortical slices. VUF 8328 is promising for research of central nervous system disorders.
    VUF 8328
Cat. No. Product Name / Synonyms Application Reactivity